STAMFORD, Conn., May 09, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. ( CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced financial results and operational highlights for the first quarter ended March 31, 2018.
Cara Therapeutics Reports First Quarter 2018 Financial Results
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться